CALGARY, Alberta, Jan. 06, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company ...
The nuclear program of India consists of three stages. The first stage involves the Pressurized Heavy Water Reactors, the second stage involves the Fast Breeder Reactors, and the third stage involves ...
Xbiome, an AI-driven microbiome therapeutics company, has acquired the clinical-stage M201 program from Assembly Biosciences, a clinical-stage biotechnology company developing innovative therapeutics ...
XORTX to focus on late stage allopurinol intolerant gout program; discussion with FDA planned for first half 2025 regarding NDA filing CALGARY, Alberta, Jan. 06, 2025 (GLOBE NEWSWIRE) -- XORTX ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Xbiome Inc., an industry leading AI driven microbiome therapeutics company, today announced that it has acquired the clinical-stage M201 program from Assembly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results